Logotipo de Valence
populares
Iniciar sesión
Loading data for OGN — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

Organon & Co.

NYSE: OGN · Precio en tiempo real · USD
13.70
-0.02 (-0.15%)
Al cierre: Aug 19, 2026, 8:00 PM
13.74
+0.07%
Fuera de horario: 6:02 PM

Organon & Co. (OGN) Stock Price, Analysis & Data

-0.15%

No hay datos disponibles

Precio de compran/a
Capitalización de mercado3.61B
Ingresos (TTM)6.13B
Beneficio neto (TTM)209M
Beta1.52
EPS (TTM)0.78
Ratio PER (TTM)17.6
Adelante PE3.77
P/B (TTM)3.58
P/S (TTM)0.59
Earnings DateNov 9, 2026
Precio de ventan/a
Volumen1,702,121
Volumen medio (20D)2,615,227
Abierto13.71
Anterior Cerrar13.72
Rango del día13.69 - 13.72
Rango de 52 semanas5.69 - 13.72
analistan/a
Precio objetivon/a
Dividendos$0.08 (0.58%)
Fecha ex dividendo14 ago 2026

Acerca de OGN

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; C...

[Leer más]
Industria Drug Manufacturers - General
Sector Healthcare
IPO Fecha May 14, 2021
Empleados 10,000
Bolsa de Valores NYSE
Símbolo bursátil OGN
Sitio web https://www.organon.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Organon & fueron 6.22B, una disminución de -2.92% en comparación con 6.4B del año anterior. Las ganancias fueron 187M, una disminución de -78.36%.

Estados financieros

Sorpresa de resultados

Organon & ha publicado sus resultados trimestrales en Jul 31, 2026:
  • Ingresos de $1.56B falla las estimaciones por $0, con -2.26% Disminución interanual.
  • EPS de 0.85 falla las estimaciones por -0.22, con -15.00% Disminución interanual.

    • Próxima publicación de resultados

    Está previsto que Organon & Co. publique sus resultados el Nov 9, 2026, antes de que se abra el mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    2 semanas hace · Zacks

    Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

    Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street es...

    news image

    2 semanas hace · Zacks

    Organon (OGN) Lags Q2 Earnings Estimates

    Organon (OGN) delivered earnings and revenue surprises of -2.30% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    2 semanas hace · Reuters

    Sun Pharma's quarterly profit jumps on strength in specialty medicines

    By Kashish Tandon July 31 (Reuters) - India's Sun Pharmaceutical Industries reported a 27% rise in first-quarter profit on Friday, driven by robust growth in its high-margin specialty medicines

    news image

    3 semanas hace · Zacks

    Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

    Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

    news image

    3 semanas hace · MarketBeat

    Organon & Co. Shareholders Clear Sun Pharma Merger Deal

    Shareholders of Organon & Co. (NYSE:OGN) approved the company’s proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting held Wednesday, according to prelimina...

    Página 1 de 2